We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
Read MoreHide Full Article
West Pharmaceutical Services, Inc. (WST - Free Report) reported third-quarter 2023 adjusted earnings per share (EPS) of $2.16, up 6.4% year over year. The figure beat the Zacks Consensus Estimate by 16.1%.
The adjustments include expenses related to the amortization of acquisition-related intangible assets.
GAAP EPS for the quarter was $2.14, up 34.6% year over year.
The company’s shares have risen 52.1% year to date compared with the industry’s growth of 8.8%. The broader S&P 500 Index has increased 10% in the same time frame.
Image Source: Zacks Investment Research
Revenues in Detail
West Pharmaceutical registered net sales of $747.4 million in the third quarter, up 8.8% year over year. The figure beat the Zacks Consensus Estimate by 0.1%.
The company recorded organic net sales growth of 5.7% in the reported quarter.
Per management, the top-line growth was driven by Proprietary Products' high-value product (HVP) and strong Contract Manufacturing component sales. However, WST’s revenues reflect a slowdown in restocking trends by large Pharma and Generic customers.
Segmental Details
West Pharmaceutical operates under two segments — Proprietary Products and Contract-Manufactured Products.
Net sales in the Proprietary Products segment were $602.5 million, indicating year-over-year growth of 6.3% reportedly and 3.2% organically. HVP net sales accounted for more than 75% of the segment’s net sales, with a strong demand for FluroTec, Daikyo, Envision and HVP devices like self-injection and administration systems.
Generics and Pharma market units of the Proprietary Products segment reflected robust organic growth in the third quarter. However, declining sales related to COVID-19 vaccines led to a double-digit percentage-point decrease in organic net sales for the Biologics market unit. Excluding COVID-19-related sales, all market units had double-digit organic net sales growth.
Net sales at the Contract-Manufactured Products segment increased 20.8% year over year to $144.9 million. Currency translation was a tailwind, boosting sales growth by 340 basis points. The segment saw a 17.4% improvement in organic net sales.
Margins
In the quarter under review, West Pharmaceutical’s gross profit increased 7.6% to $288.3 million. The gross margin contracted nearly 40 basis points (bps) to 38.6%.
Selling, general and administrative expenses rose 34.2% to $89 million. Research and development expenses went up 20.6% year over year to $16.4 million.
Adjusted operating profit totaled $180.8 million, indicating a decline of 3% from the prior-year quarter’s level. The adjusted operating margin contracted 290 bps to 24.2%.
Financial Position
West Pharmaceutical exited third-quarter 2023 with cash and cash equivalents of $898.6 million compared with $796.3 million at the end of the second quarter. Total debt at the end of the reported quarter was $207.3 million compared with $207.8 million at the end of the previous quarter.
Cumulative net cash flow from operating activities was $537.4 million compared with $493.2 million in the year-ago period.
2023 Guidance
WST raised its 2023 outlook for earnings but lowered the same for revenues.
It currently projects adjusted EPS of $7.95-$8.00, up from the previously anticipated range of $7.65-$7.80. The Zacks Consensus Estimate for the same is pegged at $7.86. Higher expectation for EPS also reflects a favorable currency impact of 7 cents, 2 cents higher than the earlier estimate.
Net sales are projected between $2.95 billion and $2.96 billion, down from the previously guided range of $2.97-$2.995 billion. The Zacks Consensus Estimate for the same is pegged at $2.98 billion. The company expects currency translation to have a positive impact of $20 million on revenues. Lower revenue outlook reflects a lower COVID-19-related sales guidance and an $8- million reduction in sales resulting from the divestiture of a European facility.
The organic sales growth estimate was 2-3%, lower than the earlier anticipated range of 3-4%.
West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise
West Pharmaceutical exited the third quarter of 2023 with better-than-expected results. The recovery in organic growth is encouraging. The company’s revenue outlook beat market estimates. However, contractions in the gross and operating margins do not bode well.
On a positive note, demand for West Pharmaceutical’s HVP products continued to be strong. Double-digit organic net sales growth in the Pharma and Generic market units is another quarterly highlight. CONMED expects the double-digit base, non-COVID-19-related organic sales growth to continue in the fourth quarter, driven by strong HVP component demand.
Zacks Rank and Other Stocks to Consider
Currently, West Pharmaceutical carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories (ABT - Free Report) , Elevance Health, Inc. (ELV - Free Report) and Edwards Lifesciences (EW - Free Report) .
Revenues of $10.14 billion outpaced the consensus mark by 3.6%.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%.
Elevance Health reported third-quarter 2023 adjusted EPS of $8.99, which beat the Zacks Consensus Estimate by 6.4%. Revenues of $42.5 billion were in line with the Zacks Consensus Estimate. The company currently carries a Zacks Rank #2.
ELV has a long-term estimated growth rate of 12.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.91%.
Edwards Lifesciences reported third-quarter 2023 adjusted EPS of 59 cents and revenues of $1.48 billion, both in line with their respective Zacks Consensus Estimate. It currently carries a Zacks Rank #2.
EW has a long-term estimated growth rate of 8%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 1.62%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
West Pharmaceutical Services, Inc. (WST - Free Report) reported third-quarter 2023 adjusted earnings per share (EPS) of $2.16, up 6.4% year over year. The figure beat the Zacks Consensus Estimate by 16.1%.
The adjustments include expenses related to the amortization of acquisition-related intangible assets.
GAAP EPS for the quarter was $2.14, up 34.6% year over year.
The company’s shares have risen 52.1% year to date compared with the industry’s growth of 8.8%. The broader S&P 500 Index has increased 10% in the same time frame.
Image Source: Zacks Investment Research
Revenues in Detail
West Pharmaceutical registered net sales of $747.4 million in the third quarter, up 8.8% year over year. The figure beat the Zacks Consensus Estimate by 0.1%.
The company recorded organic net sales growth of 5.7% in the reported quarter.
Per management, the top-line growth was driven by Proprietary Products' high-value product (HVP) and strong Contract Manufacturing component sales. However, WST’s revenues reflect a slowdown in restocking trends by large Pharma and Generic customers.
Segmental Details
West Pharmaceutical operates under two segments — Proprietary Products and Contract-Manufactured Products.
Net sales in the Proprietary Products segment were $602.5 million, indicating year-over-year growth of 6.3% reportedly and 3.2% organically. HVP net sales accounted for more than 75% of the segment’s net sales, with a strong demand for FluroTec, Daikyo, Envision and HVP devices like self-injection and administration systems.
Generics and Pharma market units of the Proprietary Products segment reflected robust organic growth in the third quarter. However, declining sales related to COVID-19 vaccines led to a double-digit percentage-point decrease in organic net sales for the Biologics market unit. Excluding COVID-19-related sales, all market units had double-digit organic net sales growth.
Net sales at the Contract-Manufactured Products segment increased 20.8% year over year to $144.9 million. Currency translation was a tailwind, boosting sales growth by 340 basis points. The segment saw a 17.4% improvement in organic net sales.
Margins
In the quarter under review, West Pharmaceutical’s gross profit increased 7.6% to $288.3 million. The gross margin contracted nearly 40 basis points (bps) to 38.6%.
Selling, general and administrative expenses rose 34.2% to $89 million. Research and development expenses went up 20.6% year over year to $16.4 million.
Adjusted operating profit totaled $180.8 million, indicating a decline of 3% from the prior-year quarter’s level. The adjusted operating margin contracted 290 bps to 24.2%.
Financial Position
West Pharmaceutical exited third-quarter 2023 with cash and cash equivalents of $898.6 million compared with $796.3 million at the end of the second quarter. Total debt at the end of the reported quarter was $207.3 million compared with $207.8 million at the end of the previous quarter.
Cumulative net cash flow from operating activities was $537.4 million compared with $493.2 million in the year-ago period.
2023 Guidance
WST raised its 2023 outlook for earnings but lowered the same for revenues.
It currently projects adjusted EPS of $7.95-$8.00, up from the previously anticipated range of $7.65-$7.80. The Zacks Consensus Estimate for the same is pegged at $7.86. Higher expectation for EPS also reflects a favorable currency impact of 7 cents, 2 cents higher than the earlier estimate.
Net sales are projected between $2.95 billion and $2.96 billion, down from the previously guided range of $2.97-$2.995 billion. The Zacks Consensus Estimate for the same is pegged at $2.98 billion. The company expects currency translation to have a positive impact of $20 million on revenues. Lower revenue outlook reflects a lower COVID-19-related sales guidance and an $8- million reduction in sales resulting from the divestiture of a European facility.
The organic sales growth estimate was 2-3%, lower than the earlier anticipated range of 3-4%.
West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise
West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote
Our Take
West Pharmaceutical exited the third quarter of 2023 with better-than-expected results. The recovery in organic growth is encouraging. The company’s revenue outlook beat market estimates. However, contractions in the gross and operating margins do not bode well.
On a positive note, demand for West Pharmaceutical’s HVP products continued to be strong. Double-digit organic net sales growth in the Pharma and Generic market units is another quarterly highlight. CONMED expects the double-digit base, non-COVID-19-related organic sales growth to continue in the fourth quarter, driven by strong HVP component demand.
Zacks Rank and Other Stocks to Consider
Currently, West Pharmaceutical carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories (ABT - Free Report) , Elevance Health, Inc. (ELV - Free Report) and Edwards Lifesciences (EW - Free Report) .
Abbott, carrying a Zacks Rank of 2 at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $10.14 billion outpaced the consensus mark by 3.6%.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%.
Elevance Health reported third-quarter 2023 adjusted EPS of $8.99, which beat the Zacks Consensus Estimate by 6.4%. Revenues of $42.5 billion were in line with the Zacks Consensus Estimate. The company currently carries a Zacks Rank #2.
ELV has a long-term estimated growth rate of 12.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.91%.
Edwards Lifesciences reported third-quarter 2023 adjusted EPS of 59 cents and revenues of $1.48 billion, both in line with their respective Zacks Consensus Estimate. It currently carries a Zacks Rank #2.
EW has a long-term estimated growth rate of 8%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 1.62%.